Moran Wealth Management LLC Boosts Stock Position in Vericel Co. (NASDAQ:VCEL)

Moran Wealth Management LLC raised its holdings in shares of Vericel Co. (NASDAQ:VCEL) by 42.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,755 shares of the biotechnology company’s stock after acquiring an additional 3,204 shares during the quarter. Moran Wealth Management LLC’s holdings in Vericel were worth $454,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Nisa Investment Advisors LLC grew its holdings in shares of Vericel by 9.7% during the second quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 220 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Vericel by 22.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 322 shares during the last quarter. PFG Investments LLC boosted its holdings in shares of Vericel by 6.2% in the second quarter. PFG Investments LLC now owns 6,850 shares of the biotechnology company’s stock valued at $314,000 after acquiring an additional 400 shares during the period. Farther Finance Advisors LLC increased its holdings in shares of Vericel by 48.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 405 shares during the period. Finally, Arizona State Retirement System increased its stake in Vericel by 3.3% in the second quarter. Arizona State Retirement System now owns 12,866 shares of the biotechnology company’s stock valued at $590,000 after purchasing an additional 406 shares during the period.

Insider Transactions at Vericel

In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total value of $724,150.00. Following the sale, the chief executive officer now directly owns 220,937 shares of the company’s stock, valued at approximately $9,142,373.06. This trade represents a 7.34 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Steven C. Gilman sold 5,833 shares of the company’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $41.36, for a total transaction of $241,252.88. Following the transaction, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $454,960. This represents a 34.65 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 29,166 shares of company stock worth $1,200,764 over the last quarter. 5.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on VCEL shares. Stephens boosted their price target on Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Canaccord Genuity Group reiterated a “buy” rating and set a $60.00 target price on shares of Vericel in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Vericel in a research report on Friday, November 8th. Canaccord Genuity Group started coverage on shares of Vericel in a research report on Friday, August 9th. They set a “buy” rating and a $57.00 price target for the company. Finally, TD Cowen upped their price target on Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, August 27th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $58.14.

Vericel Trading Up 4.2 %

Vericel stock opened at $59.11 on Friday. The stock has a market cap of $2.92 billion, a PE ratio of 985.33 and a beta of 1.66. The stock has a 50-day moving average price of $46.13 and a 200 day moving average price of $47.02. Vericel Co. has a 52 week low of $32.31 and a 52 week high of $60.15.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.03. The business had revenue of $57.91 million for the quarter, compared to the consensus estimate of $55.32 million. Vericel had a net margin of 1.56% and a return on equity of 1.48%. On average, equities analysts predict that Vericel Co. will post 0.13 EPS for the current year.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.